Search clinical trials for: Neutralizing Antibody

Total 5304 results

Novartis Pharmaceuticals

Completed

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

Psoriatic Arthritis

Germany, Netherlands, United Kingdom
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

HIV-1

United States, Puerto Rico
Rockefeller University

Completed

3BNC117-LS First-in-Human Phase 1 Study

Human Immunodeficiency Virus

United States
Imperial College London
Bill and Melinda Gates Foundation

Completed

Optimising DNA Vaccinations in Healthy Volunteers (DNAVAC001)

HIV-1-infection
National Institute of Allergy and Infectious Diseases...

Terminated

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

Healthy Adult Immune Response

United States
National Institute of Allergy and Infectious Diseases...

Completed

Challenge Infection of Healthy Adult Volunteers With RSV A2

Upper Respiratory Tract Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

HIV Prevention

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

Respiratory Syncytial Virus

United States
Rockefeller University

Completed

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

HIV Infection | Monoclonal Antibody, Human | HIV Antibodies | VRC01 Monoclonal Antibody | Neutralizing Antibody

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

HIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal Antibody

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Monoclonal Antibody, Human | HIV Antibodies | Neutralizing Antibody | Prevention of HIV Infection

United States
Rockefeller University
University Hospital of Cologne

Completed

3BNC117 and 10-1074 in HIV-infected Individuals

Human Immunodeficiency Virus (HIV)

United States, Germany
Rockefeller University

Completed

3BNC117 and 10-1074 in HIV Uninfected Adults

Human Immunodeficiency Virus

United States
National Cancer Institute (NCI)

Completed

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Leukemia | Chronic | Lymphocytic

United States
GlaxoSmithKline

Completed

A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children

Virus Diseases

China
Novartis Pharmaceuticals

Completed

Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

Psoriatic Arthritis

Germany, Netherlands, United Kingdom
Novartis Pharmaceuticals

Completed

A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Germany, United States, Belgium, Russian Federation, United Kingdom
University Hospital, Montpellier
Centre Hospitalier Universitaire de Saint Etienne; University Hospital, Clermont-Ferrand and other collaborators

Withdrawn

Non Neutralizing Antibodies: Prevalence and Characterization

Hemophilia A

France
Crucell Holland BV

Completed

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Rabies

India
Melinda Magyari
University of Copenhagen

Completed

REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients (REPAIR)

Multiple Sclerosis
Crucell Holland BV

Completed

Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents

Rabies

Philippines
RECORDATI GROUP

Completed

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension (FELT)

Essential Hypertension

France
Mahidol University
Chiron company: Clinical Research and Medical Affairs

Completed

Rabies Immunization Concomitant With JEV in Children

Rabies
Novartis
Novartis Vaccines

Completed

Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers

Japanese Encephalitis | Rabies | Pre-Exposure Prophylaxis

Thailand
Biogen

Completed

Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies (RECOVER)

Relapsing-Remitting Multiple Sclerosis

Finland
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Yuanquan Yang

Not yet recruiting

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Advanced Malignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm

United States
Fujian Cancer Hospital

Not yet recruiting

Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital

Not yet recruiting

Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery in Limited-metastatic G/GEJ Adenocarcinoma (ROSETTE)

Gastric Cancer | GastroEsophageal Cancer

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Not yet recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Generalized Myasthenia Gravis

United States, Germany
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01)

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
Unity Health Toronto

Not yet recruiting

Multiplex Near Patient Non-HCP Study

HIV Infections | Syphilis Infection
Fudan University

Recruiting

Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E2)

Early Low Rectal Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

Systemic Lupus Erythematosus (SLE) | ANCA Associated Vasculitis (AAV) | Idiopathic Inflammatory Myopathy (IIM)

China
CHU de Reims

Recruiting

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis (NETOSE)

Systemic Lupus Erythematosus | Systemic Sclerosis | Dermatomyositis | ANCA Associated Vasculitis | Other Connective Tissue Disease

France
Fundación de Investigación Biomédica - Hospital...

Recruiting

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies (PREDI-CGRP)

Migraine

Spain
Beijing 302 Hospital

Recruiting

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Chronic Hepatitis B

China
Pheon Therapeutics

Not yet recruiting

A Study of PHN-010 in Patients With Advanced Solid Tumors

Cervical Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Colon Cancer

United States
Anastasia Vishnevetsky, MD, MPH
argenx

Not yet recruiting

Efgartigimod for the Treatment of Acute Optic Neuritis (PET-AON)

Optic Neuritis

United States
Fujian Cancer Hospital
Zhangzhou Municipal Hospital of Fujian Province

Recruiting

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Cervical Cancer

China
Fudan University

Recruiting

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Rectal Cancer

China
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (ROXI-VTE II)

Venous Thromboembolism
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular Lymphoma | Refractory Grade 2 Follicular Lymphoma | Refractory Grade 3a Follicular Lymphoma

United States
Tao Lin

Not yet recruiting

Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation

Kidney Transplantation

China
Tianjin Medical University General Hospital

Not yet recruiting

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (TOMATO)

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

China
Zumutor Biologics Inc.

Recruiting

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Colorectal Cancer | Esophageal Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Pancreas Adenocarcinoma | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Biliary Tract Cancer | High Grade Ovarian Serous Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Xuanwu Hospital, Beijing

Recruiting

National, Multicentric Registry Study on Neuroimmunological Diseases in China (NIDBase)

Multiple Sclerosis | Myasthenia Gravis | Autoimmune Encephalitis | Acute Disseminated Encephalomyelitis | NMO Spectrum Disorder | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

China

Search clinical trials for: Neutralizing Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations